Showing 661 - 680 results of 103,644 for search '(( i na decrease ) OR ( 5 ((((step decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.38s Refine Results
  1. 661

    Sr<sub>2</sub>MnO<sub>2</sub>Na<sub>1.6</sub>Se<sub>2</sub>: A Metamagnetic Layered Oxychalcogenide Synthesized by Reductive Na Intercalation to Break [Se<sub>2</sub>]<sup>2–</sup>... by Souvik Giri (18700341)

    Published 2024
    “…Freshly prepared samples have 16(1) % Na-site vacancies corresponding to a formal oxidation state of Mn of +2.32, a mixed-valence between Mn<sup>2+</sup> (d<sup>5</sup>) and Mn<sup>3+</sup> (d<sup>4</sup>). …”
  2. 662

    Measurement of Na<sup>+</sup> ratio in the TE and blastocyst cross-sectional area in the ouabain-treated group. by Ayaka Fujishima (21221913)

    Published 2025
    “…The Na<sup>+</sup> concentration patterns were categorized into two main types: a decrease followed by an increase (Embryo Nos. 1, 3, 7, 9), and no significant change in Na<sup>+</sup> concentration (Embryo Nos. 2, 4, 6, 8). …”
  3. 663
  4. 664
  5. 665

    Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs by Olivier Reynard (354756)

    Published 2016
    “…In this paper, we explored whether low immunogenicity IgGs had a protective effect on a guinea pig model of Ebola virus (EBOV) infection. …”
  6. 666
  7. 667
  8. 668

    A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity by Regina Michelis (2889092)

    Published 2019
    “…In patients with abnormal C5, basal levels of sC5b-9 and C5a were increased while activities of the CP and of the CP C5-convertase, the immediate C5-upstream complex, were decreased compared to NC and to patients with normal C5. …”
  9. 669
  10. 670

    Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera by Angela Bozza (8908091)

    Published 2023
    “…After the discovery of a mutation in the Janus kinase 2 (<i>JAK</i>2<sup>V617F</sup>), JAK2 inhibitors have been tested as second-line therapies. …”
  11. 671
  12. 672
  13. 673
  14. 674
  15. 675
  16. 676
  17. 677
  18. 678
  19. 679
  20. 680